search
Back to results

A Study of Telitacicept in Patients With Primary IgA Nephropathy

Primary Purpose

IgA Nephropathy

Status
Recruiting
Phase
Phase 3
Locations
China
Study Type
Interventional
Intervention
Telitacicept
Placebo
Sponsored by
RemeGen Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for IgA Nephropathy focused on measuring Kidney Diseases, Autoimmune Diseases, Immune System Diseases

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Voluntary informed consent provided; Male or female aged ≥ 18 years old; IgA nephropathy confirmed by pathological biopsy; During the screening period, UPCR ≥ 0.5 g/g based on 24-hour urine collection at visit 1 and/or visit 2 and at visit 3; eGFR ≥ 30 mL/min per 1.73 m^2 (using the CKD-EPI); Have been on a treatment regimen including ACEI/ARB for 12 weeks and on a stable use of ACEI/ARB medication at the maximum tolerated dose/maximum allowable dose within 4 weeks prior to randomization. Subjects who use both ACEIs and ARBs will be excluded. Exclusion Criteria: Subjects with clinically significant abnormal laboratory tests; Patients with secondary IgA nephropathy; Patients with other types of glomerular disease such as crescentic glomerulonephritis, minimal change nephropathy with IgA deposition; Renal transplant; Patients with cirrhosis, as assessed by the investigator; Patients who experienced any of the following cardiovascular and cerebrovascular events within 24 weeks prior to randomization: myocardial infarction, unstable angina, ventricular arrhythmia, NYHA Class II or higher heart failure, stroke, etc.; Sitting office SBP>140 mmHg or DBP>90 mmHg during the screening period; HbA1c>8% (64mmol/mol); Treatment with immunosuppressants (cyclophosphamide, azathioprine, mycophenolate, leflunomide, tacrolimus, cyclosporine, Tripterygium wilfordii, etc.) within 12 weeks prior to randomization; Treatment with anti-CD20 therapy within 24 weeks prior to randomization; Treatment with systemic glucocorticoid within 12 weeks prior to randomization; Hospitalization or intravenous anti-infective therapy for active infection within 4 weeks prior to randomization; Patients with active tuberculosis and untreated latent tuberculosis; Hepatitis B: patients with active hepatitis (patients with positive HBsAg) or latent hepatitis B (patients with positive HBcAb and positive HBV-DNA); Patients with hepatitis C; Patients with HIV; Patients with malignancy within the past 5 years, except for treated cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, colon polyps, or cervical cancer in situ; Pregnant women, lactating women, and subjects with childbearing plans during the trial; Unavoidable use of drugs with renal toxicity during the study; Allergic to biological products of human origin; Patients who have received any investigational therapy within 4 weeks or within 5 times the half-life of the investigational product (whichever is longer) prior to randomization; Live vaccination within 4 weeks prior to randomization; Patients with COVID-19 infection within 4 weeks of randomization or patients with a history of serious COVID-19 disease requiring hospitalization within 52 weeks prior to screening; Drug or alcohol abuse/dependence within 52 weeks prior to randomization; Not suitable for the study in the opinion of the investigator.

Sites / Locations

  • The First Affiliated Hospital of Bengbu Medical College
  • The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
  • The Second Affiliated Hospital of Anhui Medical UniversityRecruiting
  • Yijishan Hospital of Wannan Medical CollegeRecruiting
  • Beijing Anzhen Hospital Affiliated to Capital Medical University
  • Beijing Hospital
  • Beijing Tsinghua Changgeng Hospital
  • Peking University First HospitalRecruiting
  • Peking University People's Hospital
  • Peking University Shougang Hospital
  • The First Affiliated Hospital of Army Medical University
  • The Second Affiliated Hospital of Chongqing Medical University
  • The First Affiliated Hospital of Xiamen University
  • Zhongshan Hospital Affiliated to Xiamen UniversityRecruiting
  • Gansu Provincial HospitalRecruiting
  • Lanzhou University Second Hospital
  • The First Hospital of Lanzhou University
  • Guangdong Provincial People's HospitalRecruiting
  • The Second Affiliated Hospital of Guangzhou Medical University
  • The Third Affiliated Hospital of Southern Medical University
  • Zhujiang Hospital of Southern Medical University
  • Shantou Central Hospital
  • Longgang District People's Hospital of Shenzhen
  • Peking University Shenzhen Hospital
  • Shenzhen Hospital of Southern Medical University
  • Shenzhen People's Hospital
  • Affiliated Hospital of Guangdong Medical University
  • Zhuhai People's Hospital
  • Affiliated Hospital of Guilin Medical CollegeRecruiting
  • Liuzhou Workers HospitalRecruiting
  • The First Affiliated Hospital of Guangxi Medical University
  • Guizhou Provincial People's Hospital
  • Affiliated Hospital of Zunyi Medical University
  • Affiliated Hospital of Hebei University
  • Cangzhou Central Hospital
  • Handan First Hospital
  • First Hospital of Qinhuangdao
  • The Second Hospital of Hebei Medical UniversityRecruiting
  • Xingtai People's Hospital
  • The First Affiliated Hospital of Hebei North University
  • The First Affiliated Hospital of Henan University of science and Technology
  • Nanyang Central Hospital
  • Henan Provincial People's Hospital
  • The First Affiliated Hospital of Zhengzhou University
  • Renmin Hospital of Wuhan UniversityRecruiting
  • Zhongnan Hospital of Wuhan UniversityRecruiting
  • The Second Xiangya Hospital of Central South University
  • The Third Xiangya Hospital of Central South University
  • Xiangya Hospital of Central South UniversityRecruiting
  • The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and TechnologyRecruiting
  • The Affiliated Hospital of Inner Mongolia Medical University
  • Changzhou No.2 People's HospitalRecruiting
  • Jiangsu Provincial People's Hospital
  • Zhongda Hospital Southeast University
  • Wuxi People's HospitalRecruiting
  • The Affiliated Hospital of Xuzhou Medical University
  • Jiangxi Provincial People's Hospital
  • The First Affiliated Hospital of Nanchang University
  • The Second Affiliated Hospital of Nanchang University
  • China-Japan Union Hospital of Jilin UniversityRecruiting
  • Jilin Province People's Hospital
  • The First Hospital of Jilin University
  • The Second Hospital of Jilin UniversityRecruiting
  • General Hospital of Northern Theatre Command of Chinese People's Liberation Army
  • Shengjing Hospital of China Medical UniversityRecruiting
  • The Affiliated Central Hospital of Shenyang Medical College
  • General Hospital of Ningxia Medical University
  • The First Affiliated Hospital of Xi'an Jiaotong UniversityRecruiting
  • The Second Affiliated Hospital of Xi'an Jiaotong University
  • Qilu Hospital of Shandong UniversityRecruiting
  • Shandong Provincial Hospital
  • Shandong Provincial Qianfoshan Hospital
  • Linyi People's HospitalRecruiting
  • The Affiliated Hospital of Qingdao UniversityRecruiting
  • Yantai Yuhuangding Hospital
  • Huashan Hospital Affiliated to Fudan University
  • Renji Hospital Affiliated to Shanghai Jiaotong University School of MedicineRecruiting
  • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
  • First Hospital of Shanxi Medical University
  • Second Hospital of Shanxi Medical University
  • Shanxi Bethune HospitalRecruiting
  • Shanxi Provincial People's HospitalRecruiting
  • Sichuan Academy of Medical Sciences & Sichuan Provincial People's HospitalRecruiting
  • West China Hospital of Sichuan University
  • The Second People's Hospital of Yibin
  • The Second Hospital of Tianjin Medical University
  • Tianjin Medical University General HospitalRecruiting
  • People's Hospital of Xinjiang Uygur Autonomous RegionRecruiting
  • The First Affiliated Hospital of Xinjiang Medical University
  • The First People's Hospital of Yunnan Province
  • The First Affiliated Hospital, Zhejiang University School of Medicine
  • Zhejiang Provincial People's Hospital
  • Jinhua Municipal Central HospitalRecruiting
  • Ningbo First Hospital
  • Ningbo No.2 Hospital
  • Ningbo Traditional Chinese Medicine Hospital
  • Taizhou Hospital of Zhejiang Province
  • The First Affiliated Hospital of Wenzhou Medical UniversityRecruiting
  • Wenzhou Central Hospital
  • Wenzhou People's HospitalRecruiting
  • Tongde Hospital of Zhejing Province

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Telitacicept

Placebo

Arm Description

Subjects will be given Telitacicept 240 mg SC once a week in phase A for a total of 39 doses and once every 2 weeks in phase B for a total of 32 doses.

Subjects will be given placebo SC once a week in phase A for a total of 39 doses and once every 2 weeks in phase B for a total of 32 doses.

Outcomes

Primary Outcome Measures

Change from baseline in urine protein creatinine ratio (UPCR) (based on a 24-hour urine sample) at Week 39
Primary endpoint of phase A
Annualized estimated glomerular filtration rate (eGFR) slope at Week 104
Primary endpoint of phase B

Secondary Outcome Measures

Change from baseline in urine protein creatinine ratio (UPCR) (based on a 24-hour urine sample) at weeks 52, 78, and 104
Change from baseline in UPCR at weeks 52, 78, and 104
Change from baseline in estimated glomerular filtration rate (eGFR) at weeks 39, 52, 78 and 104
Change from baseline in eGFR at weeks 39, 52, 78 and 104
Change from baseline in urine albumin-to-creatinine ratio (UACR) (based on a 24-hour urine sample) at weeks 39, 52, 78 and 104
Change from baseline in UACR (based on a 24-hour urine sample) at weeks 39, 52, 78 and 104
Proportion of subjects achieving urine protein creatinine ratio (UPCR) < 0.8 g/g (based on a 24-hour urine sample) at weeks 39, 52, 78 and 104
Proportion of subjects achieving UPCR < 0.8 g/g (based on a 24-hour urine sample) at weeks 39, 52, 78 and 104
Proportion of patients with a 30% decrease in estimated glomerular filtration rate (eGFR) from baseline at Week 39
Proportion of patients with a 30% decrease in eGFR from baseline at Week 39
Annualized estimated glomerular filtration rate (eGFR) slope at Week 52
Annualized eGFR slope at Week 52
Time to first occurrence of 30% decrease in estimated glomerular filtration rate (eGFR)
Time to first occurrence of 30% decrease in eGFR since the first dose of the study medicine
Proportion of subjects who received rescue therapy at weeks 52, 78, and 104
Proportion of subjects who received rescue therapy at weeks 52, 78, and 104
Time to composite endpoint event
The composite endpoint event is defined as initiation of maintenance renal dialysis (for at least 1 month), renal transplant, renal failure (eGFR < 15 mL/min/1.73 m2 or greater than 30% decrease in eGFR from baseline), or death due to renal failure.
Incidence and severity of adverse events
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

Full Information

First Posted
March 5, 2023
Last Updated
September 1, 2023
Sponsor
RemeGen Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05799287
Brief Title
A Study of Telitacicept in Patients With Primary IgA Nephropathy
Official Title
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Telitacicept in Patients With IgA Nephropathy
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 28, 2023 (Actual)
Primary Completion Date
October 2025 (Anticipated)
Study Completion Date
December 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
RemeGen Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate the efficacy and safety of Telitacicept in patients with primary IgA nephropathy.
Detailed Description
This study consists of a 5-week screening period, a double-blind treatment period divided into phase A and phase B. Eligible subjects will be randomly assigned in a 1:1 ratio to receive either Telitacicept 240mg or placebo. Subjects will be given SC Telitacicept or placebo once a week for a total of 39 doses in phase A and once every 2 weeks for a total of 32 doses in phase B. Primary endpoint of phase A will be measured at week 39. Primary endpoint of phase B will be measured at week 104.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
IgA Nephropathy
Keywords
Kidney Diseases, Autoimmune Diseases, Immune System Diseases

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
308 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Telitacicept
Arm Type
Experimental
Arm Description
Subjects will be given Telitacicept 240 mg SC once a week in phase A for a total of 39 doses and once every 2 weeks in phase B for a total of 32 doses.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Subjects will be given placebo SC once a week in phase A for a total of 39 doses and once every 2 weeks in phase B for a total of 32 doses.
Intervention Type
Biological
Intervention Name(s)
Telitacicept
Other Intervention Name(s)
RC18
Intervention Description
Telitacicept 240 mg SC
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo to Telitacicept
Primary Outcome Measure Information:
Title
Change from baseline in urine protein creatinine ratio (UPCR) (based on a 24-hour urine sample) at Week 39
Description
Primary endpoint of phase A
Time Frame
Week 39
Title
Annualized estimated glomerular filtration rate (eGFR) slope at Week 104
Description
Primary endpoint of phase B
Time Frame
Week 104
Secondary Outcome Measure Information:
Title
Change from baseline in urine protein creatinine ratio (UPCR) (based on a 24-hour urine sample) at weeks 52, 78, and 104
Description
Change from baseline in UPCR at weeks 52, 78, and 104
Time Frame
weeks 52, 78, and 104
Title
Change from baseline in estimated glomerular filtration rate (eGFR) at weeks 39, 52, 78 and 104
Description
Change from baseline in eGFR at weeks 39, 52, 78 and 104
Time Frame
weeks 39, 52, 78 and 104
Title
Change from baseline in urine albumin-to-creatinine ratio (UACR) (based on a 24-hour urine sample) at weeks 39, 52, 78 and 104
Description
Change from baseline in UACR (based on a 24-hour urine sample) at weeks 39, 52, 78 and 104
Time Frame
weeks 39, 52, 78 and 104
Title
Proportion of subjects achieving urine protein creatinine ratio (UPCR) < 0.8 g/g (based on a 24-hour urine sample) at weeks 39, 52, 78 and 104
Description
Proportion of subjects achieving UPCR < 0.8 g/g (based on a 24-hour urine sample) at weeks 39, 52, 78 and 104
Time Frame
weeks 39, 52, 78 and 104
Title
Proportion of patients with a 30% decrease in estimated glomerular filtration rate (eGFR) from baseline at Week 39
Description
Proportion of patients with a 30% decrease in eGFR from baseline at Week 39
Time Frame
Week 39
Title
Annualized estimated glomerular filtration rate (eGFR) slope at Week 52
Description
Annualized eGFR slope at Week 52
Time Frame
Week 52
Title
Time to first occurrence of 30% decrease in estimated glomerular filtration rate (eGFR)
Description
Time to first occurrence of 30% decrease in eGFR since the first dose of the study medicine
Time Frame
up to 104 weeks
Title
Proportion of subjects who received rescue therapy at weeks 52, 78, and 104
Description
Proportion of subjects who received rescue therapy at weeks 52, 78, and 104
Time Frame
weeks 52, 78, and 104
Title
Time to composite endpoint event
Description
The composite endpoint event is defined as initiation of maintenance renal dialysis (for at least 1 month), renal transplant, renal failure (eGFR < 15 mL/min/1.73 m2 or greater than 30% decrease in eGFR from baseline), or death due to renal failure.
Time Frame
up to 104 weeks
Title
Incidence and severity of adverse events
Description
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
Time Frame
up to 104 weeks
Other Pre-specified Outcome Measures:
Title
Change from baseline in 24-hour urine protein at Week 39
Description
Change from baseline in 24-hour urine protein at Week 39
Time Frame
Week 39

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Voluntary informed consent provided; Male or female aged ≥ 18 years old; IgA nephropathy confirmed by pathological biopsy; During the screening period, UPCR ≥ 0.5 g/g based on 24-hour urine collection at visit 1 and/or visit 2 and at visit 3; eGFR ≥ 30 mL/min per 1.73 m^2 (using the CKD-EPI); Have been on a treatment regimen including ACEI/ARB for 12 weeks and on a stable use of ACEI/ARB medication at the maximum tolerated dose/maximum allowable dose within 4 weeks prior to randomization. Subjects who use both ACEIs and ARBs will be excluded. Exclusion Criteria: Subjects with clinically significant abnormal laboratory tests; Patients with secondary IgA nephropathy; Patients with other types of glomerular disease such as crescentic glomerulonephritis, minimal change nephropathy with IgA deposition; Renal transplant; Patients with cirrhosis, as assessed by the investigator; Patients who experienced any of the following cardiovascular and cerebrovascular events within 24 weeks prior to randomization: myocardial infarction, unstable angina, ventricular arrhythmia, NYHA Class II or higher heart failure, stroke, etc.; Sitting office SBP>140 mmHg or DBP>90 mmHg during the screening period; HbA1c>8% (64mmol/mol); Treatment with immunosuppressants (cyclophosphamide, azathioprine, mycophenolate, leflunomide, tacrolimus, cyclosporine, Tripterygium wilfordii, etc.) within 12 weeks prior to randomization; Treatment with anti-CD20 therapy within 24 weeks prior to randomization; Treatment with systemic glucocorticoid within 12 weeks prior to randomization; Hospitalization or intravenous anti-infective therapy for active infection within 4 weeks prior to randomization; Patients with active tuberculosis and untreated latent tuberculosis; Hepatitis B: patients with active hepatitis (patients with positive HBsAg) or latent hepatitis B (patients with positive HBcAb and positive HBV-DNA); Patients with hepatitis C; Patients with HIV; Patients with malignancy within the past 5 years, except for treated cutaneous basal cell carcinoma, cutaneous squamous cell carcinoma, colon polyps, or cervical cancer in situ; Pregnant women, lactating women, and subjects with childbearing plans during the trial; Unavoidable use of drugs with renal toxicity during the study; Allergic to biological products of human origin; Patients who have received any investigational therapy within 4 weeks or within 5 times the half-life of the investigational product (whichever is longer) prior to randomization; Live vaccination within 4 weeks prior to randomization; Patients with COVID-19 infection within 4 weeks of randomization or patients with a history of serious COVID-19 disease requiring hospitalization within 52 weeks prior to screening; Drug or alcohol abuse/dependence within 52 weeks prior to randomization; Not suitable for the study in the opinion of the investigator.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Binghua Xiao
Phone
86-101-58076833
Email
binghua.xiao@remegen.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jicheng Lv, M.D.
Organizational Affiliation
Peking University First Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
The First Affiliated Hospital of Bengbu Medical College
City
Bengbu
State/Province
Anhui
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
City
Hefei
State/Province
Anhui
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The Second Affiliated Hospital of Anhui Medical University
City
Hefei
State/Province
Anhui
Country
China
Individual Site Status
Recruiting
Facility Name
Yijishan Hospital of Wannan Medical College
City
Wuhu
State/Province
Anhui
Country
China
Individual Site Status
Recruiting
Facility Name
Beijing Anzhen Hospital Affiliated to Capital Medical University
City
Beijing
State/Province
Beijing
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Beijing Hospital
City
Beijing
State/Province
Beijing
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Beijing Tsinghua Changgeng Hospital
City
Beijing
State/Province
Beijing
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Peking University First Hospital
City
Beijing
State/Province
Beijing
Country
China
Individual Site Status
Recruiting
Facility Name
Peking University People's Hospital
City
Beijing
State/Province
Beijing
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Peking University Shougang Hospital
City
Beijing
State/Province
Beijing
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The First Affiliated Hospital of Army Medical University
City
Chongqing
State/Province
Chongqing
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The Second Affiliated Hospital of Chongqing Medical University
City
Chongqing
State/Province
Chongqing
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The First Affiliated Hospital of Xiamen University
City
Xiamen
State/Province
Fujian
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Zhongshan Hospital Affiliated to Xiamen University
City
Xiamen
State/Province
Fujian
Country
China
Individual Site Status
Recruiting
Facility Name
Gansu Provincial Hospital
City
Lanzhou
State/Province
Gansu
Country
China
Individual Site Status
Recruiting
Facility Name
Lanzhou University Second Hospital
City
Lanzhou
State/Province
Gansu
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The First Hospital of Lanzhou University
City
Lanzhou
State/Province
Gansu
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Guangdong Provincial People's Hospital
City
Guangzhou
State/Province
Guangdong
Country
China
Individual Site Status
Recruiting
Facility Name
The Second Affiliated Hospital of Guangzhou Medical University
City
Guangzhou
State/Province
Guangdong
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The Third Affiliated Hospital of Southern Medical University
City
Guangzhou
State/Province
Guangdong
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Zhujiang Hospital of Southern Medical University
City
Guangzhou
State/Province
Guangdong
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Shantou Central Hospital
City
Shantou
State/Province
Guangdong
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Longgang District People's Hospital of Shenzhen
City
Shenzhen
State/Province
Guangdong
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Peking University Shenzhen Hospital
City
Shenzhen
State/Province
Guangdong
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Shenzhen Hospital of Southern Medical University
City
Shenzhen
State/Province
Guangdong
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Shenzhen People's Hospital
City
Shenzhen
State/Province
Guangdong
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Affiliated Hospital of Guangdong Medical University
City
Zhanjiang
State/Province
Guangdong
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Zhuhai People's Hospital
City
Zhuhai
State/Province
Guangdong
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Affiliated Hospital of Guilin Medical College
City
Guilin
State/Province
Guangxi Zhuang Autonomous Region
Country
China
Individual Site Status
Recruiting
Facility Name
Liuzhou Workers Hospital
City
Liuzhou
State/Province
Guangxi Zhuang Autonomous Region
Country
China
Individual Site Status
Recruiting
Facility Name
The First Affiliated Hospital of Guangxi Medical University
City
Nanning
State/Province
Guangxi Zhuang Autonomous Region
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Guizhou Provincial People's Hospital
City
Guiyang
State/Province
Guizhou
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Affiliated Hospital of Zunyi Medical University
City
Zunyi
State/Province
Guizhou
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Affiliated Hospital of Hebei University
City
Baoding
State/Province
Hebei
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Cangzhou Central Hospital
City
Cangzhou
State/Province
Hebei
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Handan First Hospital
City
Handan
State/Province
Hebei
Country
China
Individual Site Status
Not yet recruiting
Facility Name
First Hospital of Qinhuangdao
City
Qinhuangdao
State/Province
Hebei
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The Second Hospital of Hebei Medical University
City
Shijiazhuang
State/Province
Hebei
Country
China
Individual Site Status
Recruiting
Facility Name
Xingtai People's Hospital
City
Xingtai
State/Province
Hebei
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The First Affiliated Hospital of Hebei North University
City
Zhangjiakou
State/Province
Hebei
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The First Affiliated Hospital of Henan University of science and Technology
City
Luoyang
State/Province
Henan
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Nanyang Central Hospital
City
Nanyang
State/Province
Henan
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Henan Provincial People's Hospital
City
Zhengzhou
State/Province
Henan
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The First Affiliated Hospital of Zhengzhou University
City
Zhengzhou
State/Province
Henan
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Renmin Hospital of Wuhan University
City
Wuhan
State/Province
Hubei
Country
China
Individual Site Status
Recruiting
Facility Name
Zhongnan Hospital of Wuhan University
City
Wuhan
State/Province
Hubei
Country
China
Individual Site Status
Recruiting
Facility Name
The Second Xiangya Hospital of Central South University
City
Changsha
State/Province
Hunan
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The Third Xiangya Hospital of Central South University
City
Changsha
State/Province
Hunan
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Xiangya Hospital of Central South University
City
Changsha
State/Province
Hunan
Country
China
Individual Site Status
Recruiting
Facility Name
The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
City
Baotou
State/Province
Inner Mongolia Autonomous Region
Country
China
Individual Site Status
Recruiting
Facility Name
The Affiliated Hospital of Inner Mongolia Medical University
City
Hohhot
State/Province
Inner Mongolia Autonomous Region
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Changzhou No.2 People's Hospital
City
Changzhou
State/Province
Jiangsu
Country
China
Individual Site Status
Recruiting
Facility Name
Jiangsu Provincial People's Hospital
City
Nanjing
State/Province
Jiangsu
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Zhongda Hospital Southeast University
City
Nanjing
State/Province
Jiangsu
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Wuxi People's Hospital
City
Wuxi
State/Province
Jiangsu
Country
China
Individual Site Status
Recruiting
Facility Name
The Affiliated Hospital of Xuzhou Medical University
City
Xuzhou
State/Province
Jiangsu
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Jiangxi Provincial People's Hospital
City
Nanchang
State/Province
Jiangxi
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The First Affiliated Hospital of Nanchang University
City
Nanchang
State/Province
Jiangxi
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The Second Affiliated Hospital of Nanchang University
City
Nanchang
State/Province
Jiangxi
Country
China
Individual Site Status
Not yet recruiting
Facility Name
China-Japan Union Hospital of Jilin University
City
Changchun
State/Province
Jilin
Country
China
Individual Site Status
Recruiting
Facility Name
Jilin Province People's Hospital
City
Changchun
State/Province
Jilin
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The First Hospital of Jilin University
City
Changchun
State/Province
Jilin
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The Second Hospital of Jilin University
City
Changchun
State/Province
Jilin
Country
China
Individual Site Status
Recruiting
Facility Name
General Hospital of Northern Theatre Command of Chinese People's Liberation Army
City
Shenyang
State/Province
Liaoning
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Shengjing Hospital of China Medical University
City
Shenyang
State/Province
Liaoning
Country
China
Individual Site Status
Recruiting
Facility Name
The Affiliated Central Hospital of Shenyang Medical College
City
Shenyang
State/Province
Liaoning
Country
China
Individual Site Status
Not yet recruiting
Facility Name
General Hospital of Ningxia Medical University
City
Yinchuan
State/Province
Ningxia Hui Autonomous Region
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The First Affiliated Hospital of Xi'an Jiaotong University
City
Xi'an
State/Province
Shaanxi
Country
China
Individual Site Status
Recruiting
Facility Name
The Second Affiliated Hospital of Xi'an Jiaotong University
City
Xi'an
State/Province
Shaanxi
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Qilu Hospital of Shandong University
City
Jinan
State/Province
Shandong
Country
China
Individual Site Status
Recruiting
Facility Name
Shandong Provincial Hospital
City
Jinan
State/Province
Shandong
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Shandong Provincial Qianfoshan Hospital
City
Jinan
State/Province
Shandong
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Linyi People's Hospital
City
Linyi
State/Province
Shandong
Country
China
Individual Site Status
Recruiting
Facility Name
The Affiliated Hospital of Qingdao University
City
Qingdao
State/Province
Shandong
Country
China
Individual Site Status
Recruiting
Facility Name
Yantai Yuhuangding Hospital
City
Yantai
State/Province
Shandong
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Huashan Hospital Affiliated to Fudan University
City
Shanghai
State/Province
Shanghai
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
City
Shanghai
State/Province
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Name
Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
City
Shanghai
State/Province
Shanghai
Country
China
Individual Site Status
Not yet recruiting
Facility Name
First Hospital of Shanxi Medical University
City
Taiyuan
State/Province
Shanxi
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Second Hospital of Shanxi Medical University
City
Taiyuan
State/Province
Shanxi
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Shanxi Bethune Hospital
City
Taiyuan
State/Province
Shanxi
Country
China
Individual Site Status
Recruiting
Facility Name
Shanxi Provincial People's Hospital
City
Taiyuan
State/Province
Shanxi
Country
China
Individual Site Status
Recruiting
Facility Name
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital
City
Chengdu
State/Province
Sichuan
Country
China
Individual Site Status
Recruiting
Facility Name
West China Hospital of Sichuan University
City
Chengdu
State/Province
Sichuan
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The Second People's Hospital of Yibin
City
Yibin
State/Province
Sichuan
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The Second Hospital of Tianjin Medical University
City
Tianjin
State/Province
Tianjin
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Tianjin Medical University General Hospital
City
Tianjin
State/Province
Tianjin
Country
China
Individual Site Status
Recruiting
Facility Name
People's Hospital of Xinjiang Uygur Autonomous Region
City
Urumqi
State/Province
Xinjiang Uygur Autonomous Region
Country
China
Individual Site Status
Recruiting
Facility Name
The First Affiliated Hospital of Xinjiang Medical University
City
Urumqi
State/Province
Xinjiang Uygur Autonomous Region
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The First People's Hospital of Yunnan Province
City
Kunming
State/Province
Yunnan
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The First Affiliated Hospital, Zhejiang University School of Medicine
City
Hangzhou
State/Province
Zhejiang
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Zhejiang Provincial People's Hospital
City
Hangzhou
State/Province
Zhejiang
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Jinhua Municipal Central Hospital
City
Jinhua
State/Province
Zhejiang
Country
China
Individual Site Status
Recruiting
Facility Name
Ningbo First Hospital
City
Ningbo
State/Province
Zhejiang
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Ningbo No.2 Hospital
City
Ningbo
State/Province
Zhejiang
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Ningbo Traditional Chinese Medicine Hospital
City
Ningbo
State/Province
Zhejiang
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Taizhou Hospital of Zhejiang Province
City
Taizhou
State/Province
Zhejiang
Country
China
Individual Site Status
Not yet recruiting
Facility Name
The First Affiliated Hospital of Wenzhou Medical University
City
Wenzhou
State/Province
Zhejiang
Country
China
Individual Site Status
Recruiting
Facility Name
Wenzhou Central Hospital
City
Wenzhou
State/Province
Zhejiang
Country
China
Individual Site Status
Not yet recruiting
Facility Name
Wenzhou People's Hospital
City
Wenzhou
State/Province
Zhejiang
Country
China
Individual Site Status
Recruiting
Facility Name
Tongde Hospital of Zhejing Province
City
Hangzhou
State/Province
Zhejing
Country
China
Individual Site Status
Not yet recruiting

12. IPD Sharing Statement

Learn more about this trial

A Study of Telitacicept in Patients With Primary IgA Nephropathy

We'll reach out to this number within 24 hrs